- Research article
- Open Access
Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study
BMC Cancer volume 9, Article number: 347 (2009)
The anti-VEGF antibody bevacizumab associated with an irinotecan or oxaliplatin-based chemotherapy was proved to be superior to the chemotherapy alone in first or second line treatment of metastatic colorectal cancer (mCRC). However, it was reported to have no efficacy in 3rd or later-line, alone or with 5FU. The aim of this study was to evaluate the activity of bevacizumab combined with FOLFIRI or FOLFOX in mCRC who have failed prior chemotherapy with fluoropyrimidine plus irinotecan and/or oxaliplatin.
Thirty one consecutive patients treated between May 2005 and October 2006 were included in this retrospective study. All of them have progressed under a chemotherapy with fluoropyrimidine plus irinotecan and/or oxaliplatin and received bevacizumab (5 mg/kg) in combination with FOLFIRI or simplified FOLFOX4 every 14 days.
Ten patients (32.2%) had an objective response (1 CR, 9 PR) and 12 (38.8%) were stabilized. The response and disease control rates were 45.4% and 100% when bevacizumab was administered in 2nd or 3rd line and 25% and 55% in 4th or later line respectively (p = 0.024 and p = 0.008). Among the patients who had previously received the same chemotherapy than that associated with bevacizumab (n = 28) the overall response rate was 35.7% and 39.3% were stabilized. Median progression free survival (PFS) and overall survival (OS) were of 9.7 and 18.4 months respectively. Except a patient who presented a hypertension associated reversible posterior leukoencephalopathy syndrome, tolerance of bevacizumab was acceptable. A rectal bleeding occurred in one patient, an epistaxis in five. Grade 1/2 hypertension occurred in five patients.
This study suggests that bevacizumab combined with FOLFOX or FOLFIRI may have the possibility to be active in chemorefractory and selected mCRC patients who did not receive it previously.
Colorectal cancer (CRC) is one of the most common human malignancies with more than 300,000 cases both in the United States and in the European Union each year. In the past decade, significant improvements have been performed in response rates, progression-free survival (PFS) and overall survival (OS) [1–4]. Despite these improvements, mainly due to the development of new combinations of standard chemotherapy including 5 fluorouracil, irinotecan and oxaliplatin, nearly all patients with metastatic CRC (mCRC) will die from their disease. Recently, new therapeutic agents targeting molecular events involved in colorectal carcinogenesis have been developed, including bevacizumab, a recombinant humanized monoclonal antibody, which binds to the vascular endothelial growth factor (VEGF) with a high specificity and prevents its interaction with receptors on endothelial cells. VEGF plays a key role in angiogenesis, which is involved in the development of carcinogenesis, tumor growth and malignant dissemination. Therefore, bevacizumab inhibits the activation of VEGF-receptor-mediated signaling pathways and resultant biological effects . This antiangiogenic agent, added to a 5-fluorouracil (5FU) ± irinotecan-based chemotherapy as first-line treatment, has been shown to improve response rates and survival of mCRC patients when compared to the chemotherapy alone [6–8]. An improvement of PFS was also shown in first-line with the addition of bevacizumab to oxaliplatin-based chemotherapy . A randomized phase III study also reported a clinical efficacy of the association of bevacizumab and FOLFOX4 as second-line in mCRC patients previously treated with a fluoropyrimidine and irinotecan, with a significant improvement in response rates, PFS and OS when compared to FOLFOX4 alone .
In Europe, bevacizumab was approved by the EMEA (European Medicines Evaluation Agency) in the beginning of 2005 and many CRC patients could not have received it in first or second-line treatment before this date. Moreover, it was reported to have no efficacy in 3rd or later-line, alone or with 5FU [10, 11]. The aim of this retrospective study was to evaluate the activity of bevacizumab combined with a chemotherapy with 5FU/LV and irinotecan or oxaliplatin in mCRC who have failed prior chemotherapy with fluoropyrimidine plus irinotecan and/or oxaliplatin.
In this retrospective study, we included all the patients prospectively registered in two centers (Hôpital Ambroise Paré, Boulogne Billancourt and Centre Régional de Lutte contre le Cancer Val d'Aurelle, Montpellier, France) with histologically proven mCRC who had been previously treated with a fluoropyrimidine (e.g., fluorouracil or capecticabine) plus irinotecan and/or oxaliplatin with no response to treatment (as defined by tumor progression according to the RECIST criteria  or unacceptable toxicity) and who then received bevacizumab in combination with FOLFIRI or simplified FOLFOX4 between May 2005 and October 2006. The decision of treatment was always taken during multidisciplinary staff for patients who had not the opportunity to receive bevacizumab at an earlier line of chemotherapy. The usual exclusion criteria were a history of major surgery within 28 days, a thrombotic or bleeding event within 6 months, a hypertension, a clinically significant cardiovascular disease, a hypertension, a therapeutic anticoagulation and the presence of brain metastases. All medical files of the patients were registered prospectively in a computerised database (after national registry council (CNIL) authorization). The following data were collected and analyzed: age and performance status (according to WHO criteria) at the time of the first cycle of bevacizumab, gender, primary tumor site (colon or rectum), number and localization of metastatic sites, previous anticancer drugs received and tumor response to them. This retrospective study was proposed in January 2007 and approved by the local scientific and ethical committee.
Patients were treated with bevacizumab given at a dose of 5 mg/kg on day 1 every two weeks, followed by a 2-hour infusion of 400 mg/m2 of leucovorin, given simultaneously with a 2-hour infusion of 85 mg/m2 of oxaliplatin, followed by a bolus of 400 mg/m2 of 5FU and then a 46-hour infusion of 2400 mg/m2 of 5FU (simplified FOLFOX4) or the same regimen with a 90 minutes (min) infusion of 180 mg/m2 of irinotecan instead of the infusion of oxaliplatin (FOLFIRI) (1 cycle = 14 days). The first infusion of bevacizumab was given over 90 min, the second over 60 min and the following over 30 min when previous infusions were well tolerated.
All the patients must have received at least four cycles of chemotherapy with bevacizumab to be evaluable, but two patients had evidence of a clinical progression before the radiologic evaluation of tumor response and received only three cycles of bevacizumab.
Tumour response was prospectively assessed every four cycles according to RECIST criteria by computerized tomography-scan. Treatment was repeated until the occurrence of disease progression or unacceptable toxicity.
Toxicity was assessed according to the Common Toxicity Criteria version 2.0.
Fisher's exact test was used to compare response and stabilization rates between groups. The PFS was calculated as the period from the first day of bevacizumab treatment to the date of tumor progression, to death from any cause or to the date of the last follow-up at which data point was censored. The OS time was calculated as the period from the first day of bevacizumab treatment until death of any cause or until the date of the last follow-up, at which data point was censored. Both PFS and OS were estimated by the Kaplan-Meier method and compared using the log-rank test. Analysis was carried out using the STATA software package (College Station, Texas). The level of significance was set at p = 0.05.
Between May 2005 and October 2006, a total of 31 patients (17 men, 14 women, median age: 60 years) with mCRC resistant to fluoropyrimidine plus irinotecan (96.7%) and/or oxaliplatin (90.3%) received bevacizumab combined with FOLFIRI or FOLFOX4. A total of 373 cycles of bevacizumab combined with chemotherapy were administered, with a median of 12 cycles per patient (range: 3 to 35 cycles).
Patients characteristics are detailed in the table 1. All the patients had a good WHO performance status (≤ 2) at the beginning of bevacizumab therapy except one (WHO PS = 3). The number of metastatic sites were limited to one or two organs in 77% of the cases (24 patients), and metastases were mostly located in the liver (84%) or lung (42%). Twenty seven patients (87%) had previously received fluoropyrimidine, irinotecan and oxaliplatin and 19 (61%) had received cetuximab. In 19 out of 20 patients who received bevacizumab in 4th-line or further (L4+), cetuximab was previously used and failed, five patients previously received a monotherapy of fluoropyrimidine (capecitabine ou 5FU), four patients were treated by the association of capecitabine and mitomycin-C and five by hepatic arterial infusion of oxaliplatin and intraveinous LV5FU2. Bevacizumab was combined with FOLFIRI in 19 cases and with FOLFOX in 12 cases and was administered equally as third, fourth and fifth or later-line (32% in each group). One patient was treated in second line but he was progressive under a combination of 5FU, irinotecan and oxaliplatine (FOLFIRINOX regimen).
The overall response rate was 32.2% (table 2). One patient (3.2%) had a complete response and 9 (29%) a partial response. Among them, one patient could have a resection of liver metastases after a partial response to FOLFIRI plus bevacizumab and was alive without relapse at the last follow-up. Twelve patients (38.8%) had a stable disease, with a disease control rate of 71%. The response rate was 45.4% when bevacizumab was administered in 2nd and 3rd-line (L2-L3) and 25% when it was administered in 4th-line and further (L4+) respectively (table 2; p = 0.024). It was 36.9% when bevacizumab was associated with FOLFIRI and 25% when associated with FOLFOX (p = 0.6). The disease control rate was 100% when bevacizumab was administered in L2-L3 and 55% when it was administered in L4+ respectively (table 2; p = 0.008). Most of the patients (n = 28; 90%) had previously received the same chemotherapy (FOLFOX or FOLFIRI) than that associated with bevacizumab. Among these patients, the overall response rate was 35.7% and 39.3% were stabilized (table 2).
With a median follow-up period of 35.9 months (range: 33 to 37.4 months) from the beginning of bevacizumab administration, the median PFS was 9.7 months (95% confidence interval (CI): 6.6-13.6) (figure 1) and the median OS was 18.4 months (95%CI: 13.6- not reached) (figure 2).
There was no toxic death. The incidence of haematological and non-hematological toxicity is summarized in Table 3. A grade 3/4 toxic event occurred in 19,3% of patients. A cytotoxic dose reduction or interruption and a delay in chemotherapy cycles was required in 51% and 13% of patients respectively. As concerns bevacizumab-induced toxicity, only one interruption was required in a patient who presented a reversible posterior leukoencephalopathy syndrome attributed to bevacizumab therapy because of associated hypertension. This syndrome was revealed by a generalized tonic-clonic seizure and diagnosed on magnetic resonance imaging of the brain . Except this severe adverse event, tolerance of bevacizumab was acceptable, without bowel perforation, thromboembolism event, severe bleeding or hypertension. A minimal rectal bleeding occurred in one patient and a grade 1/2 hypertension in five patients, which was easily manageable by an antihypertensive treatment. An epistaxis also occurred in five patients.
This study reports an activity of bevacizumab at the dose of 5 mg/kg combined with FOLFOX or FOLFIRI regimen in patients who have failed prior chemotherapy with fluoropyrimidine, irinotecan and/or oxaliplatin. Indeed, 32% of the patients could achieved an objective response and one patient could secondary have a curative resection of its liver metastases. The disease control rate was superior to 70%. The addition of bevacizumab to FOLFIRI or FOLFOX was also associated with a PFS and a OS of 9.7 months and 18.4 months respectively. These response and survival rates are higher than those reported by Giantonio et al. with the combination of FOLFOX plus bevacizumab in second line treatment in patients previously treated by fluoropyrimidine and irinotecan, but this might be certainly explained by the small size and the retrospective nature of our study. Furthermore, patients who received bevacizumab during the period of the study were highly selected because bevacizumab was not registered in this setting but only in first line treatment. For these reasons, our results have to be taken with caution. However, they are nonetheless interesting in third-line treatment where few molecules have been shown to be effective. In patients pretreated with fluroropyrimidine, irinotecan and/or oxaliplatin, several studies have reported poor response and survival rates with standard chemotherapy such as the association of mitomycine C and capecitabine [15–18]. The antibodies against the Epidermal Growth Factor Receptor (EGFR) are the only therapy to have shown their efficacy in chemorefractory CRC patients. Cetuximab was the first to show a significant response rate in association with irinotecan in irinotecan-refractory mCRC in the phase II BOND study, in which PFS and OS were of 4.1 and 8.6 months respectively . The superiority of cetuximab monotherapy over best supportive care (BSC) in terms of survival was demonstrate more recently . The fully human anti-EGFR antibody panitumumab was also associated with a longer PFS when compared to BSC in a recent randomized phase III trial . However, it is now clearly demonstrated that patients with a tumor KRAS mutation are resistant to anti-EGFR antibodies and do not benefit from this targeted therapy [22–26]. Bevacizumab should therefore be considered for these patients after failure of conventional chemotherapy. In our study, 61% of the patients had previously received cetuximab and were so resistant to all potentially efficient therapies approved in the treatment of mCRC.
In patients who were previously treated with the same chemotherapy regimen (90% of all patients included), the addition of bevacizumab to this regimen allowed a response rate of 35.7% and a stabilization of 39.3%, which suggests that the antiangiogenic therapy may circumvent resistance to conventional chemotherapy by allowing a more efficient delivery of chemotherapeutic agents. Tumor vasculature is structurally and functionally abnormal, which results in an heterogeneity in tumor blood flow with interstitial hypertension, hypoxia and acidosis . Hypoxia could therefore renders tumor cells resistant to several cytotoxic drugs by interfering with the penetration of these drugs throughout the tumor. The concept of "normalization" of tumor vasculature induced by bevacizumab, developed by Jain  who demonstrated with some colleagues this effect of VEGF blockade in rectal carcinoma , may therefore explain the circumvention of resistance to conventional therapies observed in our study. This phenomenon do not seem to be observed with the combination of an anti-EGFR antibody with bevacizumab considering the disappointing results of two recent randomized studies in which the addition of cetuximab or panitumumab to bevacizumab in combination with a conventional chemotherapy was not associated with any benefit but on the contrary perhaps with a deleterious effect [30, 31], which remains to be elucidated.
A first randomized phase II trial of bevacizumab plus bolus 5FU/LV compared to 5FU/LV alone in untreated mCRC suggested an improvement of response rate, PFS and OS with the combined treatment . Then, the large randomized phase III study reported by Hurwitz et al.  demonstrated that the addition of bevacizumab to irinotecan and bolus 5FU/LV (IFL regimen) in first-line treatment was associated with a significant prolongation of PFS (6.2 months versus 10.6 months) and OS (15.6 months versus 20.3 months), as a better response rate (34.8% versus 44.8%). The results of that pivotal study led to the registration of bevacizumab in the fist-line setting in the United States and in Europe. The association of bevacizumab to 5FU/LV was also shown to provide a statistically significant and clinically relevant benefit to patients with previously untreated mCRC [6–8, 32]. More recent studies showed that bevacizumab with FOLFIRI or FOLFOX4 regimen was superior to the chemotherapy alone in this setting [9, 33]. In second-line, the ECOG E3200 phase III trial showed that bevacizumab improved response rate, PFS and OS when added to the FOLFOX4 regimen in patients pre-treated with a fluoropyrimidine and irinotecan . Bevacizumab in combination with 5FU/LV plus irinotecan or oxaliplatin is therefore proved to be beneficial in first and 2nd-line setting. In the absence of cross-over after progression in the chemotherapy arm of the studies evaluating the addition of bevacizumab to a combined chemotherapy [6, 10], the effect of the antiangiogenic agent associated with a bichemotherapy after the 2nd-line of treatment is not known. However, it was associated with a poor response rate (1%) in combination with a bolus regimen of 5FU/LV in chemotherapy-refractory mCRC . In this large multicenter phase II study, PFS and OS were 3.7 months and 9.1 months respectively. This result, adding to the lack of efficacy of bevacizumab in monotherapy led us to test it in this setting in combination with the more active FOLFOX4 or FOLFIRI regimens. Bevacizumab was administrated at the dose of 5 mg/kg every 2 weeks as it was reported in first-line studies with 5FU/LV/irinotecan or oxaliplatin [6, 9, 33] and since the 10 mg/kg dose was not previously shown to be superior .
Our results are consistent with those of a recent small study conducted in 14 mCRC patients that progressed after oxaliplatin and irinotecan and for whom bevacizumab plus infusional 5FU/LV and irinotecan allowed a 28.5% response rate with 57% of stabilized patients . Median PFS was 3.9 months and OS was 10.9 months.
In our study, bevacizumab was well tolerated, with only one interruption due to a reversible posterior leukoencephalopathy syndrome associated with hypertension . The other adverse events were easily manageable. As concerns chemotherapy-induced toxicity, it was relatively low because most of the patients previously received the same regimen as that associated with bevacizumab. Therefore required dose modifications were already performed before starting bevacizumab therapy
Taking together, these results from retrospective data suggest that bevacizumab combined with FOLFOX or FOLFIRI may have the possibility to be active in chemorefractory and selected mCRC patients who did not receive it previously.
de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, et al: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000, 18 (16): 2938-2947.
Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, et al: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet. 2000, 355 (9209): 1041-1047. 10.1016/S0140-6736(00)02034-1.
Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC, Alberts SR: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2004, 22 (1): 23-30. 10.1200/JCO.2004.09.046.
Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, et al: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med. 2000, 343 (13): 905-914. 10.1056/NEJM200009283431302.
Ferrara N: Molecular and biological properties of vascular endothelial growth factor. J Mol Med. 1999, 77 (7): 527-543. 10.1007/s001099900019.
Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004, 350 (23): 2335-2342. 10.1056/NEJMoa032691.
Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, Griffing S, Bergsland E: Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol. 2003, 21 (1): 60-65. 10.1200/JCO.2003.10.066.
Kabbinavar FF, Schulz J, McCleod M, Patel T, Hamm JT, Hecht JR, Mass R, Perrou B, Nelson B, Novotny WF: Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol. 2005, 23 (16): 3697-3705. 10.1200/JCO.2005.05.112.
Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, et al: Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008, 26 (12): 2013-2019. 10.1200/JCO.2007.14.9930.
Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, Schwartz MA, Benson AB: Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007, 25 (12): 1539-1544. 10.1200/JCO.2006.09.6305.
Chen HX, Mooney M, Boron M, Vena D, Mosby K, Grochow L, Jaffe C, Rubinstein L, Zwiebel J, Kaplan RS: Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: an NCI Treatment Referral Center Trial TRC-0301. J Clin Oncol. 2006, 24 (21): 3354-3360. 10.1200/JCO.2005.05.1573.
Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, et al: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000, 92 (3): 205-216. 10.1093/jnci/92.3.205.
Common Toxicity Criteria (CTC) v2.0. [http://cancer.gov/]
El Maalouf G, Mitry E, Lacout A, Lievre A, Rougier P: Isolated brainstem involvement in posterior reversible leukoencephalopathy induced by bevacizumab. J Neurol. 2008, 255 (2): 295-296. 10.1007/s00415-008-0692-2.
Chong G, Dickson JL, Cunningham D, Norman AR, Rao S, Hill ME, Price TJ, Oates J, Tebbutt N: Capecitabine and mitomycin C as third-line therapy for patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan. Br J Cancer. 2005, 93 (5): 510-514. 10.1038/sj.bjc.6602733.
Lim DH, Park YS, Park BB, Ji SH, Lee J, Park KW, Kang JH, Lee SH, Park JO, Kim K, et al: Mitomycin-C and capecitabine as third-line chemotherapy in patients with advanced colorectal cancer: a phase II study. Cancer Chemother Pharmacol. 2005, 56 (1): 10-14. 10.1007/s00280-004-0963-2.
Rao S, Cunningham D, Price T, Hill ME, Ross PJ, Tebbutt N, Norman AR, Oates J, Shellito P: Phase II study of capecitabine and mitomycin C as first-line treatment in patients with advanced colorectal cancer. Br J Cancer. 2004, 91 (5): 839-843.
Rimassa L, Gullo G, Carnaghi C, Abbadessa G, Zuradelli M, Tronconi MC, Pressiani T, Santoro A: Chemotherapy with mitomycin C and capecitabine in patients with advanced colorectal cancer pretreated with irinotecan and oxaliplatin. Tumori. 2006, 92 (4): 285-289.
Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, et al: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004, 351 (4): 337-345. 10.1056/NEJMoa033025.
Jonker DJ, O'Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au HJ, Berry SR, Krahn M, Price T, Simes RJ, et al: Cetuximab for the treatment of colorectal cancer. N Engl J Med. 2007, 357 (20): 2040-2048. 10.1056/NEJMoa071834.
Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, Canon JL, Van Laethem JL, Maurel J, Richardson G, et al: Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol. 2007, 25 (13): 1658-1664. 10.1200/JCO.2006.08.1620.
Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, et al: Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008, 26 (10): 1626-1634. 10.1200/JCO.2007.14.7116.
Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, Zanon C, Moroni M, Veronese S, Siena S, Bardelli A: Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res. 2007, 67 (6): 2643-2648. 10.1158/0008-5472.CAN-06-4158.
De Roock W, Piessevaux H, De Schutter J, Janssens M, De Hertogh G, Personeni N, Biesmans B, Van Laethem JL, Peeters M, Humblet Y, et al: KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol. 2008, 19 (3): 508-515. 10.1093/annonc/mdm496.
Di Fiore F, Blanchard F, Charbonnier F, Le Pessot F, Lamy A, Galais MP, Bastit L, Killian A, Sesboue R, Tuech JJ, et al: Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. Br J Cancer. 2007, 96 (8): 1166-1169. 10.1038/sj.bjc.6603685.
Lievre A, Bachet JB, Boige V, Cayre A, Le Corre D, Buc E, Ychou M, Bouche O, Landi B, Louvet C, et al: KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol. 2008, 26 (3): 374-379. 10.1200/JCO.2007.12.5906.
Padera TP, Stoll BR, Tooredman JB, Capen D, di Tomaso E, Jain RK: Pathology: cancer cells compress intratumour vessels. Nature. 2004, 427 (6976): 695-10.1038/427695a.
Jain RK: Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005, 307 (5706): 58-62. 10.1126/science.1104819.
Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, Tong RT, Chung DC, Sahani DV, Kalva SP, Kozin SV, et al: Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med. 2004, 10 (2): 145-147. 10.1038/nm988.
Hecht JR, Mitchell E, Chidiac T, Scroggin C, Hagenstad C, Spigel D, Marshall J, Cohn A, McCollum D, Stella P, et al: A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol. 2009, 27 (5): 672-680. 10.1200/JCO.2008.19.8135.
Tol J, Koopman M, Cats A, Rodenburg CJ, Creemers GJ, Schrama JG, Erdkamp FL, Vos AH, van Groeningen CJ, Sinnige HA, et al: Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med. 2009, 360 (6): 563-572. 10.1056/NEJMoa0808268.
Kabbinavar FF, Hambleton J, Mass RD, Hurwitz HI, Bergsland E, Sarkar S: Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol. 2005, 23 (16): 3706-3712. 10.1200/JCO.2005.00.232.
Fuchs CS, Marshall J, Mitchell E, Wierzbicki R, Ganju V, Jeffery M, Schulz J, Richards D, Soufi-Mahjoubi R, Wang B, et al: Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol. 2007, 25 (30): 4779-4786. 10.1200/JCO.2007.11.3357.
Kwon HC, Oh SY, Lee S, Kim SH, Kim HJ: Bevacizumab plus infusional 5-fluorouracil, leucovorin and irinotecan for advanced colorectal cancer that progressed after oxaliplatin and irinotecan chemotherapy: a pilot study. World J Gastroenterol. 2007, 13 (46): 6231-6235. 10.3748/wjg.13.6231.
The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/9/347/prepub
Grant support: AROLD association (Association de Recherche en OncoLogie Digestive, Hopital Ambroise Paré; 92100 Boulogne, France)
AL and MY: received honoraria from Roche France
PR: received research grant from Roche France
AL, JBB, ES, CBG collected the clinical data. AL, ES, EM, EA, CL, JBB, FP, JNV, MY and PR treated and followed the patients included in the study. PR, EM, MY and AL were involved in the conception of the study. EM performed the statistical analysis. AL wrote the manuscript. ES, EM, PR and MY were involved in the interpretation of data and critically revised the manuscript. All the authors read and approved the final manuscript.
Authors’ original submitted files for images
Below are the links to the authors’ original submitted files for images.
Rights and permissions
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
About this article
Cite this article
Lièvre, A., Samalin, E., Mitry, E. et al. Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study. BMC Cancer 9, 347 (2009). https://doi.org/10.1186/1471-2407-9-347
- Overall Survival
- Progression Free Survival